Advertisement
Advertisement
TGTX
TG Therapeutics, Inc.
33.73
USDSponsored
-0.91
-2.63%
Apr 10, 16:00 UTC -4
Closed
Pre-Market
33.60
-0.13
-0.39%
TGTX Earnings Reports
Positive Surprise Ratio
TGTX beat 12 of 41 last estimates.
29%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$202.63M
/$0.30
Implied change from Q4 25 (Revenue/ EPS)
+5.22%
/+114.29%
Implied change from Q1 25 (Revenue/ EPS)
+67.66%
/+900.00%
TG Therapeutics, Inc. earnings per share and revenue
On Feb 26, 2026, TGTX reported earnings of 0.14 USD per share (EPS) for Q4 25, missing the estimate of 0.35 USD, resulting in a -60.93% surprise. Revenue reached 192.57 million, compared to an expected 196.06 million, with a -1.78% difference. The market reacted with a +5.99% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of 0.30 USD, with revenue projected to reach 202.63 million USD, implying an increase of 114.29% EPS, and increase of 5.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Fortress Biotech, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.01
Surprise
-108.91%
OS Therapies Incorporated
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.50
Surprise
-260.49%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were TG Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, TG Therapeutics, Inc. reported EPS of $0.14, missing estimates by -60.93%, and revenue of $192.57M, -1.78% below expectations.
How did the market react to TG Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved up 5.99%, changed from $27.87 before the earnings release to $29.54 the day after.
When is TG Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for TG Therapeutics, Inc.'s next earnings report?
Based on --
analysts, TG Therapeutics, Inc. is expected to report EPS of $0.30 and revenue of $202.63M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement